Seoul, South Korea  Lotte Biologics is making significant strides in expanding its global presence in the Contract Development and Manufacturing Organization (CDMO) space, with a strong focus on North America and Asia. Under the leadership of CEO James Park, the company has intensified its growth strategy, highlighted by major infrastructure investments and new contract wins.

This year, Lotte Biologics marked a key milestone with the completion of its Antibody-Drug Conjugate (ADC) production facility at its Syracuse Bio Campus in New York, USA. The upgraded site has already secured its first production contract, establishing the company’s foothold in the high-growth ADC market.

Lotte Biologics entered the CDMO market in 2022 through the acquisition of Bristol Myers Squibb’s biologics manufacturing plant in Syracuse. Since then, the company has integrated advanced quality systems and standardized manufacturing processes, positioning itself as a global competitor in biologics and ADC production.

As part of its innovation roadmap, Lotte Biologics is also advancing its proprietary ADC platform, Soluflex Link™. This new technology enhances the hydrophilicity and solubility of linker-payloads, improving drug efficacy and stability for a wide range of therapeutic applications.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

The company is simultaneously constructing a large-scale bio campus in Songdo, South Korea, with the first facility expected to be operational by 2027. While the Syracuse site functions as a North American one-stop CDMO hub, the upcoming Songdo campus is being developed as a large-scale production base to support global manufacturing demands.

Lotte Biologics is further strengthening its CDMO capabilities through strategic collaborations with biotech firms across the globe. These partnerships span contract development (CDO), cell line development, and platform innovations such as ADC technology development. By aligning with both domestic and international partners, the company aims to deliver integrated, reliable CDMO solutions.

Backed by its growing track record, Lotte Biologics is actively securing manufacturing agreements with U.S.-based pharmaceutical companies, as well as European and biotech firms, reinforcing its position as a global CDMO leader.

Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com